CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 332 enrolled
Drug / intervention
5ARI +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01386983
NCT01386983N/ACompleted
CompareCT.gov

Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment

GlaxoSmithKline·observational·Posted Jul 1, 2011·Updated May 17, 2017

In Brief

An observational study evaluating 5ARI and 5ARI + AB for Prostatic Hyperplasia. Completed, enrolled 332 participants.

Detailed Summary

This retrospective study aims to assess the clinical and economic impact of early initiation of 5-alpha-reductase inhibitor (5ARI) therapy in patients with enlarged prostate (EP) receiving 5ARI monotherapy or combination therapy with an alpha-blocker (AB) compared to late initiation of 5ARI therapy in patients receiving combination therapy. The Henry Ford Health System databases will be utilized for this study (2000-2008).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsProstatic Hyperplasia
Countries--
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 1, 2011
Enrollment StartMar 1, 2009
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.0 years ago

Interventions

5ARIdrug

Dutasteride or Finasteride

5ARI + ABdrug

5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin